The Novartis CEO warned that Trump's drug pricing policy poses a “very difficult situation” and the reality will soon catch ...

Eli Lilly's deal with Profluent, Erasca's RAS-targeting cancer pill, and more biotech news today ...

In this edition of STAT Health Tech newsletter: a conversation with Google's clinical director, an update on Doctronic's Utah ...

Eli Lilly's deal with Profluent aims to go beyond CRISPR by using AI-designed enzymes to insert entire genes. It could ...

Theresa Gaffney is the lead Morning Rounds writer and reports on health care, new research, and public policy, with a ...

This could be the start of serious action on microplastics. Or it could end up as a headline with little behind it,” write ...

Google's clinical director Megan Bell Jones on how the company is addressing concerns over mental health impacts of its AI ...

WASHINGTON — Democrats and Republicans are at odds over a consequential health care policy embedded in last year’s tax cut ...

Failing to adopt a more inclusive concept of brain health represents a massive loss of human potential,” write Husseini K.

Policy that recommends offering hep B vaccine at birth only to babies perceived to be at risk will lead to increased numbers ...

The drugmaker Erasca said results on its experimental pill in a trial of pancreatic cancer and non-small cell lung cancer ...

The Supreme Court seemed divided Monday over whether to block thousands of lawsuits alleging the maker of the weedkiller ...